Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | SMMT |
---|---|---|
09:32 ET | 70033 | 11.04 |
09:34 ET | 35252 | 11.1337 |
09:36 ET | 34876 | 11.125 |
09:38 ET | 21667 | 11.16 |
09:39 ET | 24649 | 11.145 |
09:41 ET | 13138 | 11.12 |
09:43 ET | 14627 | 11.1599 |
09:45 ET | 10747 | 11.06 |
09:48 ET | 7150 | 11.15 |
09:50 ET | 15980 | 11.1304 |
09:52 ET | 10369 | 11.16 |
09:54 ET | 73033 | 11.42 |
09:56 ET | 40560 | 11.5 |
09:57 ET | 25405 | 11.44 |
09:59 ET | 19984 | 11.39 |
10:01 ET | 33053 | 11.5712 |
10:03 ET | 11476 | 11.555 |
10:06 ET | 20142 | 11.565 |
10:08 ET | 28293 | 11.385 |
10:10 ET | 7834 | 11.37 |
10:12 ET | 20597 | 11.51 |
10:14 ET | 58086 | 11.26 |
10:15 ET | 64272 | 11.245 |
10:17 ET | 2335 | 11.215 |
10:19 ET | 17188 | 11.18 |
10:21 ET | 8241 | 11.205 |
10:24 ET | 6343 | 11.16 |
10:26 ET | 21551 | 11.115 |
10:28 ET | 26231 | 11.18 |
10:30 ET | 16276 | 11.05 |
10:32 ET | 45373 | 11.07 |
10:33 ET | 18498 | 11.1245 |
10:35 ET | 13940 | 11.21 |
10:37 ET | 9881 | 11.23 |
10:39 ET | 6786 | 11.2 |
10:42 ET | 5446 | 11.2492 |
10:44 ET | 5023 | 11.22 |
10:46 ET | 5395 | 11.215 |
10:48 ET | 6400 | 11.3 |
10:50 ET | 7905 | 11.27 |
10:51 ET | 4337 | 11.26 |
10:53 ET | 8148 | 11.3 |
10:55 ET | 8704 | 11.3 |
10:57 ET | 14154 | 11.3 |
11:00 ET | 2936 | 11.32 |
11:02 ET | 30454 | 11.3 |
11:04 ET | 1205 | 11.3 |
11:06 ET | 400 | 11.28 |
11:08 ET | 3584 | 11.33 |
11:09 ET | 5394 | 11.37 |
11:11 ET | 9583 | 11.375 |
11:13 ET | 6294 | 11.3799 |
11:15 ET | 17588 | 11.345 |
11:18 ET | 7978 | 11.36 |
11:20 ET | 13707 | 11.3 |
11:22 ET | 7155 | 11.37 |
11:24 ET | 7880 | 11.3855 |
11:26 ET | 16473 | 11.4499 |
11:27 ET | 16278 | 11.4435 |
11:29 ET | 12382 | 11.4 |
11:31 ET | 5090 | 11.4 |
11:33 ET | 5051 | 11.3868 |
11:36 ET | 13012 | 11.37 |
11:38 ET | 20083 | 11.425 |
11:40 ET | 1481 | 11.4105 |
11:42 ET | 3790 | 11.395 |
11:44 ET | 2689 | 11.3784 |
11:45 ET | 1100 | 11.35 |
11:47 ET | 2000 | 11.33 |
11:49 ET | 4960 | 11.4 |
11:51 ET | 2875 | 11.395 |
11:54 ET | 4785 | 11.34 |
11:56 ET | 6439 | 11.32 |
11:58 ET | 4437 | 11.2901 |
12:00 ET | 1800 | 11.3 |
12:02 ET | 2306 | 11.315 |
12:03 ET | 2050 | 11.35 |
12:05 ET | 1273 | 11.3005 |
12:07 ET | 32151 | 11.34 |
12:09 ET | 2343 | 11.3199 |
12:12 ET | 4879 | 11.33 |
12:14 ET | 19950 | 11.39 |
12:16 ET | 7225 | 11.4501 |
12:18 ET | 12147 | 11.466 |
12:20 ET | 2300 | 11.459 |
12:21 ET | 4839 | 11.47 |
12:23 ET | 5750 | 11.465 |
12:25 ET | 13113 | 11.48 |
12:27 ET | 21345 | 11.63 |
12:30 ET | 27584 | 11.54 |
12:32 ET | 6371 | 11.52 |
12:34 ET | 9803 | 11.535 |
12:36 ET | 181552 | 11.4299 |
12:38 ET | 18191 | 11.5173 |
12:39 ET | 38372 | 11.6 |
12:41 ET | 21907 | 11.5213 |
12:43 ET | 5296 | 11.54 |
12:45 ET | 8247 | 11.5581 |
12:48 ET | 7032 | 11.514 |
12:50 ET | 6184 | 11.52 |
12:52 ET | 15020 | 11.49 |
12:54 ET | 2641 | 11.5 |
12:56 ET | 4311 | 11.57 |
12:57 ET | 22694 | 11.6 |
12:59 ET | 7913 | 11.625 |
01:01 ET | 18266 | 11.597 |
01:03 ET | 10042 | 11.57 |
01:06 ET | 6612 | 11.64 |
01:08 ET | 7100 | 11.58 |
01:10 ET | 3907 | 11.5863 |
01:12 ET | 17236 | 11.61 |
01:14 ET | 10134 | 11.6106 |
01:15 ET | 3826 | 11.575 |
01:17 ET | 2602 | 11.55 |
01:19 ET | 943 | 11.516 |
01:21 ET | 6736 | 11.484 |
01:24 ET | 4926 | 11.5 |
01:26 ET | 3502 | 11.51 |
01:28 ET | 12830 | 11.48 |
01:30 ET | 1998 | 11.5 |
01:32 ET | 1247 | 11.5 |
01:33 ET | 4812 | 11.49 |
01:35 ET | 9482 | 11.4303 |
01:37 ET | 7027 | 11.47 |
01:39 ET | 25177 | 11.45 |
01:42 ET | 6264 | 11.54 |
01:44 ET | 3593 | 11.5 |
01:46 ET | 36389 | 11.41 |
01:48 ET | 25791 | 11.45 |
01:50 ET | 2747 | 11.43 |
01:51 ET | 4807 | 11.385 |
01:53 ET | 3931 | 11.38 |
01:55 ET | 5084 | 11.39 |
01:57 ET | 1336 | 11.42 |
02:00 ET | 6800 | 11.46 |
02:02 ET | 500 | 11.48 |
02:04 ET | 17673 | 11.58 |
02:06 ET | 1592 | 11.54 |
02:08 ET | 11148 | 11.5122 |
02:09 ET | 951 | 11.52 |
02:11 ET | 2426 | 11.5 |
02:13 ET | 975 | 11.4987 |
02:15 ET | 16762 | 11.51 |
02:18 ET | 1600 | 11.5 |
02:20 ET | 5411 | 11.47 |
02:22 ET | 2900 | 11.49 |
02:24 ET | 3000 | 11.52 |
02:26 ET | 529 | 11.53 |
02:27 ET | 4039 | 11.5303 |
02:29 ET | 7097 | 11.535 |
02:31 ET | 1059 | 11.52 |
02:33 ET | 4567 | 11.5 |
02:36 ET | 1300 | 11.53 |
02:38 ET | 8150 | 11.53 |
02:40 ET | 12177 | 11.515 |
02:42 ET | 6294 | 11.46 |
02:44 ET | 3321 | 11.51 |
02:45 ET | 9257 | 11.5 |
02:47 ET | 3129 | 11.54 |
02:49 ET | 7137 | 11.5 |
02:51 ET | 8483 | 11.515 |
02:54 ET | 2622 | 11.485 |
02:56 ET | 1266 | 11.49 |
02:58 ET | 2528 | 11.51 |
03:00 ET | 2890 | 11.48 |
03:02 ET | 1364 | 11.48 |
03:03 ET | 2900 | 11.48 |
03:05 ET | 2598 | 11.45 |
03:07 ET | 528 | 11.47 |
03:09 ET | 5190 | 11.51 |
03:12 ET | 2772 | 11.53 |
03:14 ET | 13553 | 11.52 |
03:16 ET | 15996 | 11.5 |
03:18 ET | 800 | 11.51 |
03:20 ET | 4045 | 11.54 |
03:21 ET | 29030 | 11.59 |
03:23 ET | 6362 | 11.6 |
03:25 ET | 9101 | 11.58 |
03:27 ET | 24148 | 11.58 |
03:30 ET | 4888 | 11.59 |
03:32 ET | 6666 | 11.54 |
03:34 ET | 5384 | 11.53 |
03:36 ET | 24143 | 11.5099 |
03:38 ET | 8369 | 11.51 |
03:39 ET | 5203 | 11.505 |
03:41 ET | 8272 | 11.53 |
03:43 ET | 6091 | 11.54 |
03:45 ET | 16592 | 11.53 |
03:48 ET | 5101 | 11.53 |
03:50 ET | 15266 | 11.53 |
03:52 ET | 18927 | 11.51 |
03:54 ET | 47003 | 11.515 |
03:56 ET | 59542 | 11.55 |
03:57 ET | 37306 | 11.58 |
03:59 ET | 97581 | 11.55 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Summit Therapeutics Inc | 7.4B | -69.7x | --- |
Viking Therapeutics Inc | 7.2B | -70.4x | --- |
Revolution Medicines Inc | 7.5B | -12.4x | --- |
Cytokinetics Inc | 6.8B | -11.0x | --- |
Cerevel Therapeutics Holdings Inc | 8.1B | -16.4x | --- |
Madrigal Pharmaceuticals Inc | 6.0B | -12.3x | --- |
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician and caregiver medicinal therapies. The Company's development candidate is ivonescimab, a potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. It develops ivonescimab in non-small cell lung cancer (NSCLC), specifically launching Phase III clinical trials in the indications such as ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (HARMONi), and ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (HARMONi-3). Its ivonescimab is engineered with Akeso's Tetrabody technology.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $7.4B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 702.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -1.01 |
EPS | $-0.17 |
Book Value | $0.11 |
P/E Ratio | -69.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.